Q-omics provides the consensus-scored RPS16P2 profile across patient tissues and cancer cell-line models. RPS16P2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RPS16P2 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, RPS16P2 RNA expression shows 8,036 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight CHOL, HNSC, and BRCA as cancer lineages where RPS16P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS16P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS16P2 survival associations across molecular data types. RPS16P2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS16P2 RNA expression–survival associations across cancer types. High RPS16P2 expression shows unfavorable associations in CHOL, OV, SARC and HNSC, but favorable associations in SKCM and UCS. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify CHOL as the clearest survival context for RPS16P2 RNA expression.
This table summarizes RPS16P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS16P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS16P2 shows lower tumor expression in LUAD, LUSC and READ and higher tumor expression in HNSC, UCEC and LIHC. The HNSC box plot shows higher RPS16P2 RNA expression in tumor versus normal tissue (log2 FC = +1.091, t-test p < 0.001).
This table shows molecular features associated with RPS16P2 in patient tissues and cancer cell lines. In patient samples, RPS16P2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
